Compare Medpace Holdings Inc (MEDP) vs QXO Inc. Common Stock (QXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs QXO Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while QXO Inc. Common Stock trades at $10.36 (market cap $11.43B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and QXO Inc. Common Stock for 0 Days on average.
| MEDP | QXO | |
|---|---|---|
Market Cap | $17.02B | $11.43B |
Volume | 155,250 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $630.19 | $27.07 |
52-Week Low | $393.42 | $10.33 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.63B | $16.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →
